DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Ottawa Marriott Hotel

2017年10月16日 (月) 午前 7:00 - 2017年10月16日 (月) 午後 5:00

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

Canadian Pharmacovigilance and Risk Management Strategies Conference

概要

DIA’s Canadian Pharmacovigilance and Risk Management Strategies Conference is the premier place to hear from expert pharmaceutical, biotechnology, and regulatory personnel about Global Regulatory Guidance Document updates (pharmacovigilance, risk management, and drug safety), gain new perspectives from the Inspectorate, and discuss patient support programs and PV responsibilities. Join in on an exclusive session with the Canadian regulator, touching on a host of current topics including the management of Canada Vigilance Adverse Reaction Online Database duplicate safety reports.


On-Demand Complimentary Webinar

Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
On-Demand
This webinar will review Health Canada’s requirements for Plain Language Labeling for over-the-counter medicines. Presenters will walk through key recently finalized and revised guidance documents to help industry comply with these requirements and identify strategies to help industry add Drug Facts Tables to packaging while minimizing the need for packaging increases. Register today!


DIA's Canadian Health Care Content Roundup


NEW! This year DIA's Canadian Pharmacovigilance and Risk Management Conference will be co-located with the DIA Canadian Annual Meeting. Maximize your education and time by attending both!
While our conference is currently in development, check out last year’s program to see what’s in store!
View Program.

Featured

Want to learn more about Canadian Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Continuing-Education

参加対象

Professionals involved in:

  • Advertising and Promotion
  • Biotechnology
  • Clinical Data Management/eClinical
  • CMC
  • Combination Products
  • Clinical Safety and Pharmacovigilance
  • Clinical Research
  • Medical Devices and Diagnostics
  • Pharmacology
  • Regulatory Affairs

学習目的

At the conclusion of this activity, participants should be able to:

  • Describe the current Canadian regulatory framework for pharmacovigilance
  • Examine current Pharmacovigilance issues facing Marketing Authorization Holders in Canada
  • Discuss proposed changes to Vanessa’s Law
  • Identify strategies for implementing benefit-risk analyses and risk management plans

プログラム委員会

  • Rita  Cassola, RPh
    Rita Cassola, RPh Executive Director PV
    Certus PV Services Inc, Canada
  • Marcia  Bailey, BSN, MHS, RN
    Marcia Bailey, BSN, MHS, RN Safety Evaluation and Risk Management Scientific Director
    GSK, Canada
  • Colin  D'Cunha, MD, MHS, FRCPC
    Colin D'Cunha, MD, MHS, FRCPC Director, Global Medical Affairs
    Apotex Inc., Canada
  • Ljubica  Ivanisevic, PhD
    Ljubica Ivanisevic, PhD Scientific Evaluator
    Health Canada, Canada
  • Marc  Poitras, PhD, MBA
    Marc Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。